# Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19

> **NCT04607928** · PHASE2 · UNKNOWN · sponsor: **Institut d'Investigació Biomèdica de Bellvitge** · enrollment: 148 (estimated)

## Conditions studied

- Fibrotic Pulmonary Sequelae Post-COVID19 Infection

## Interventions

- **DRUG:** Pirfenidone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04607928
- **Lead sponsor:** Institut d'Investigació Biomèdica de Bellvitge
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-08-01
- **Primary completion:** 2022-01-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 148 (ESTIMATED)
- **Last updated:** 2021-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04607928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04607928, "Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04607928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*